What do studies say about Abnehmspritze Genetik?

Research on the genetics of weight loss injections (GLP-1 receptor agonists like semaglutide) is still emerging. Well-studied obesity genes such as FTO (e.g., rs9939609) show a small but consistent effect on baseline BMI – about 0.3–0.4 kg/m² per risk allele – but this does not directly predict response to the injection. Preliminary GWAS have identified variants in the GLP1R gene that may modestly influence weight loss under liraglutide or semaglutide, but effect sizes are small and findings have not been robustly replicated. Lifestyle factors, adherence, and comorbidities play a much larger role. A DNA test alone cannot determine who will benefit from these drugs. Importantly, weight loss injections are prescription medications and require medical supervision. Current evidence is moderate: some genetic associations exist, but no clinical guidelines recommend genetic testing before prescribing. The practical impact of genetic testing in this context remains limited.